In last trading session, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) saw 0.38 million shares changing hands with its beta currently measuring 0.38. Company’s recent per share price level of $0.32 trading at -$0.01 or -4.11% at ring of the bell on the day assigns it a market valuation of $1.99M. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.33 million shares which gives us an average trading volume of 1.56 million if we extend that period to 3-months.
For Cyclacel Pharmaceuticals Inc (CYCC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.29 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Upright in the red during last session for losing -4.11%, in the last five days CYCC remained trading in the red while hitting it’s week-highest on Wednesday, 12/18/24 when the stock touched $0.32 price level, adding 14.39% to its value on the day. Cyclacel Pharmaceuticals Inc’s shares saw a change of -88.11% in year-to-date performance and have moved -12.10% in past 5-day. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) showed a performance of -14.52% in past 30-days. Number of shares sold short was 66765.0 shares which calculate 0.03 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 1 to the stock, which implies a rise of 68.0% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 1. It follows that stock’s current price would drop -212.5% in reaching the projected high whereas dropping to the targeted low would mean a loss of -212.5% for stock’s current value.
Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts
Statistics highlight that Cyclacel Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -80.91% of value to its shares in past 6 months, showing an annual growth rate of 92.71% while that of industry is 17.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -87.38% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 10k for the same. And 1 analysts are in estimates of company making revenue of 25k in the next quarter. Company posted 31k and 29k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.13% during past 5 years.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Insiders are in possession of 4.82% of company’s total shares while institution are holding 18.03 percent of that, with stock having share float percentage of 18.94%. Investors also watch the number of corporate investors in a company very closely, which is 18.03% institutions for Cyclacel Pharmaceuticals Inc that are currently holding shares of the company.
